Cell-based therapy in ischemic stroke

David C Hess, Cesar V. Borlongan

Research output: Contribution to journalReview article

80 Citations (Scopus)

Abstract

Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

Original languageEnglish (US)
Pages (from-to)1193-1201
Number of pages9
JournalExpert Review of Neurotherapeutics
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Cell- and Tissue-Based Therapy
Stroke
Brain Injuries
Transplantation
Bone Marrow
Clinical Trials
Therapeutics

Keywords

  • Cell-based therapy
  • Marrow stromal cell
  • Mesenchymal stem cell
  • Phase I clinical trial
  • Restorative therapy
  • Stem cell

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cell-based therapy in ischemic stroke. / Hess, David C; Borlongan, Cesar V.

In: Expert Review of Neurotherapeutics, Vol. 8, No. 8, 01.08.2008, p. 1193-1201.

Research output: Contribution to journalReview article

Hess, David C ; Borlongan, Cesar V. / Cell-based therapy in ischemic stroke. In: Expert Review of Neurotherapeutics. 2008 ; Vol. 8, No. 8. pp. 1193-1201.
@article{c2214f129d4b43ff9ba4ded17a9beccc,
title = "Cell-based therapy in ischemic stroke",
abstract = "Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.",
keywords = "Cell-based therapy, Marrow stromal cell, Mesenchymal stem cell, Phase I clinical trial, Restorative therapy, Stem cell",
author = "Hess, {David C} and Borlongan, {Cesar V.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1586/14737175.8.8.1193",
language = "English (US)",
volume = "8",
pages = "1193--1201",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Cell-based therapy in ischemic stroke

AU - Hess, David C

AU - Borlongan, Cesar V.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

AB - Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

KW - Cell-based therapy

KW - Marrow stromal cell

KW - Mesenchymal stem cell

KW - Phase I clinical trial

KW - Restorative therapy

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=49449112789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449112789&partnerID=8YFLogxK

U2 - 10.1586/14737175.8.8.1193

DO - 10.1586/14737175.8.8.1193

M3 - Review article

VL - 8

SP - 1193

EP - 1201

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 8

ER -